World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 5
Page: 403-407

DESIGN OF EXPERIMENTS (DOE) IN PHARMACEUTICS: A COMPREHENSIVE REVIEW

Ramya Teja Medarametla*[1], Dr. J. N. Suresh Kumar[2], A. Raja Kumar[3], A. Bindhu Sri[3], A. Shaik Kousar[3], R. Sravanthi[3], D. Saida[3]

[1]Associate Professor, Department of Pharmaceutics, Narasaraopet Institute of Pharmaceutical Sciences, Narasaraopet, AP-522601.

[2]Professor and Principal, Department of Pharmaceutics, Narasaraopet Institute of Pharmaceutical Sciences, Narasaraopet, AP-522601.

[3]Research Scholar, Department of Pharmaceutics, Narasaraopet Institute of Pharmaceutical Sciences, Narasaraopet, AP-522601.

Article Received: 29 August 2025 | | ***Article Revised: 19 September 2025*** | | ***Article Accepted: 10 October 2025***

***Corresponding Author: Ramya Teja Medarametla**
Associate Professor, Department of Pharmaceutics, Narasaraopet institute of Pharmaceutical Sciences, Narasaraopet, AP-522601.
DOI: https://doi.org/10.5281/zenodo.17368650

How to cite this Article: Ramya Teja Medarametla, Dr. J. N. Suresh Kumar, A. Raja Kumar, A. Bindhu Sri, A. Shaik Kousar R. Sravanthi, D. Saida (2025) DESIGN OF EXPERIMENTS (DOE) IN PHARMACEUTICS: A COMPREHENSIVE REVIEW. World Journal of Pharmaceutical Science and Research, 4(5), 403-407. https://doi.org/10.5281/zenodo.17368650

ABSTRACT

Planning experiments in a methodical way helps scientists create and enhance drug formulas and production techniques in a scientific way. By studying different factors together, DOE can identify important materials, processes, and qualities that affect how well a drug works. DOE makes things more efficient by cutting down on the number of experiments needed and by finding hidden relationships between different factors, which is better than older, less efficient methods. This review covers key DOE techniques such as factorial designs, Response Surface Methodology (RSM), mixture designs, and optimal designs, which are used in different types of drug delivery systems like oral, transdermal, and injectable forms. It also looks into Quality by Design (QbD) from a regulatory perspective, including how Bayesian and adaptive designs, alongside machine learning, are used. The article concludes by pointing out successful methods and current trends in making reliable, affordable, and legally approved medicines.

KEYWORDS: Design of Experiments (DoE), Quality by Design (QbD), Response Surface Methodology (RSM), Pharmaceutical Formulation, Process Optimization.

INTRODUCTION[1,2]

Design of Experiments (DOE) is a method that uses statistics to plan, conduct, analyze, and understand controlled experiments. In the field of pharmacy, where ensuring quality, effectiveness, and meeting regulations are crucial, DOE offers smart ways to discover which factors have the biggest impact on the final product. It helps in understanding how these factors affect important quality traits and in setting up conditions that lead to consistent, reliable results. Compared to the traditional approach of changing one factor at a time, DOE is more efficient, finds hidden connections between factors, and creates models that help in making better choices for making and producing drugs. Pharmaceutical development often involves many challenges that make DOE especially useful. Modern drugs frequently involve a wide range of factors, such as the properties of the drug itself, the amounts of other ingredients, or how manufacturing conditions such as mixing speed or drying temperature are set. Each of these can influence key outcomes like the amount of active drug present, how well it dissolves, the size of the particles, and how stable the product is. These factors often interact in complex and nonlinear ways, and these interactions can significantly impact the final product.

Regulations like Quality by Design (QbD) and ICH guidelines encourage using scientific and risk-based methods, such as DOE, to define acceptable ranges of conditions and control strategies. Over time, the pharmaceutical industry has used various types of DOE, including screening methods like Plackett-Burman and fractional factorial designs, Response Surface Methodology (RSM), mixture designs, and optimal designs. For studies that are costly or have limited resources, sequential and Bayesian designs are used to efficiently explore possible conditions.Recent developments include combining DOE with machine learning to handle complex problems and using DOE in continuous manufacturing environments. This review brings together the latest methodological advances and real- world applications of DOE in pharmaceutics, highlighting its role in developing formulations, improving manufacturing processes, and aligning with regulatory standards.

DOE Methods in Pharmaceutics[2,3]

Screening Designs

Screening designs help identify which factors are most important from a large number of possibilities. Plackett-Burman (PB) and fractional factorial designs are often used early in development to reduce the number of experiments needed while identifying main effects. They are useful for narrowing down which excipients and process conditions should be focused on.

Full and Fractional Designs

Full factorial designs look at all possible combinations of factors and are preferred when there are not too many factors to consider. Fractional factorial designs are more efficient since they test fewer combinations. These are helpful when experiments involve multiple factors and are conducted early in the development phase.

Response Surface Methodology (RSM)

RSM includes methods like Central Composite Design (CCD) and Box-Behnken Design (BBD) and is widely used for optimization in the pharmaceutical industry. RSM provides mathematical models that describe how factors relate to outcomes, allowing the prediction of the best conditions and the visualization of these relationships through graphs.

Mixture Designs

Mixture designs are important when the outcome depends on the relative amounts of different components rather than

their absolute quantities. They are frequently used in products like emulsions and nanoparticles that consist of multiple parts.

Optimal Designs

Optimal designs, such as D-optimal, select the most useful set of experiments within defined limits. They are especially useful for expensive studies, like those involving biologics and vaccines, where the number of batches is limited.

Sequential and Adaptive Designs

Sequential experiments involve collecting data in stages, allowing for refining models as more information becomes available. Adaptive and Bayesian methods use knowledge gained from previous experiments to guide future ones, focusing on areas where the most uncertainty remains and reducing overall costs.

Practical Considerations

Important factors to consider include randomizing experiments, grouping similar conditions, repeating experiments for reliability, and selecting the right range of factors. The responses measured should reflect Critical Quality Attributes (CQAs). The adequacy of models should be checked using residual analysis and lack-of-fit tests. Compliance with regulatory standards like ICH Q8 requires keeping detailed records of the experimental design, ANOVA tables, and confirmation runs.

Emerging Trends and Future Directions

New research is exploring the combination of DOE with machine learning, Process Analytical Technology (PAT), and continuous manufacturing. Advanced Bayesian and sequential designs are being studied to optimize experiments where sample availability is limited or experiments are costly. Future studies may focus on automated methods for selecting experimental designs and AI-powered platforms for optimized formulation development.

Comparison of DoE Methods in Pharmaceutics[3,4,5]

Design Type	Purpose	Strengths	Limitations
Full Factorial	Study main effects & interactions	Complete information, interpretable	Becomes costly with many factors
Fractional Factorial	Screen factors with fewer runs	Economical, identifies main effects	May confound higher-order interactions
Central Composite Design (CCD)	Optimization & response surface modeling	Good prediction, supports curvature	Requires more runs than BBD
Box–Behnken Design (BBD)	Optimization with fewer runs	Efficient for quadratic models	Not suitable for extreme factor levels
Mixture Design	Optimize proportions of formulation components	Handles proportion constraints	Cannot vary total amount independently
D-optimal Design	Work with irregular	Flexibility, minimal runs	Requires software support & expertise

REPRESENTATIVE APPLICATIONS OF DOE IN PHARMACEUTICS[4,5,6]

Dosage Form	DoE Method	Factors Optimized	Responses (CQAs)	Example Reference
Immediate- release Tablet	3^2 Full Factorial	Binder %, isintegrant %	Disintegration time, dissolution %	Author et al., 2022
Nano suspension	CCD (RSM)	Stabilizer %, Homogenization speed	Particle size, PDI, zeta potential	Author et al., 2023
Lipid Nanoparticle	Mixture Design	Lipid: Surfactant: Co-surfactant ratio	Entrapment efficiency, release profile	Author et al., 2021
Transdermal Patch	BBD	Polymer blend, plasticizer %	Drug flux, mechanical strength	Author et al., 2020
Analytical Method Development	D-optimal	pH, mobile phase ratio	Resolution, tailing factor	Author et al., 2024

EXAMPLE RSM MODEL

In pharmaceutical optimization, a second-order polynomial model is typically fitted as

$$Y = \beta_0 + \Sigma\beta_i X_i + \Sigma\beta_{ii} X_i^2 + \Sigma\beta_{ij} X_i X_j + \varepsilon$$

Where Y is the response (e.g., dissolution %), X_i are the factors, β are regression coefficients, and ε is the experimental error. This model enables prediction and plotting of response surfaces.

BEST-PRACTICE CHECKLIST FOR APPLYING DOE IN PHARMACEUTICS

- Clearly define objectives (screening vs optimization)
- Select meaningful factors and realistic level.
- Randomize experimental runs to reduce errors.
- Include center points and replicates for model validation.
- Use ANOVA and diagnostic plots to verify model adequacy.
- Conduct confirmation runs to validate predicted optimum.
- Document all steps for regulatory submissions.

ADVANCED AND EMERGING DOE APPROACHES

1. Bayesian and Adaptive DoE

- Incorporates prior knowledge to refine experimental runs.
- Reduces material usage in costly formulations like biologics.

2. Integration with Machine Learning

- Surrogate models predict outcomes in complex formulations.
- Can combine DoE and AI to accelerate optimization.

3. Continuous Manufacturing

- Supports real-time process monitoring and adaptive control.
- Examples: Continuous granulation, tableting, inline dissolution monitoring.

4. DoE for Stability Studies

- Identifies factors affecting long-term product stability.
- Enables accelerated stability study planning



CONCLUSION

DoE has emerged as an indispensable instrument in pharmaceutical research, aiding in swift factor evaluation, process refinement, and the creation of dependable production techniques. Its incorporation into QbD structures aligns with regulatory standards, enhancing product uniformity. The advancement of computational tools and integrated approaches will enhance the application of DOE in pharmaceutical research**.**

REFERENCES

1. Patil SD. A brief review on application of design of experiment for the optimization of pharmaceutical formulations. J Young Pharm, 2024; 16(1): 1–6.
2. Rampado R, et al. Design of experiments in the optimization of nanoparticle-based drug delivery systems. J Control Release, 2023; 357: 1–16.
3. Gurba-Bryśkiewicz L, et al. Quality by design approach with design of experiment for the development of lipid nanoparticles for RNA delivery. Pharmaceutics, 2023; 15(5): 1234.
4. Wang F. Advanced experiment design strategies for drug formulation optimization. Adv Drug Deliv Rev, 2025; 178: 1–16.
5. Serrano ACCL, et al. The Use of Design of Experiments (DoE) Approaches for Self-Emulsifying Drug Delivery Systems (SEDDS) Development. Pharmaceutics, 2025; 6(1): 4.
6. Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery systems using systematic 'design of experiments.' Part II: Retrospect and prospects. Crit Rev Ther Drug Carrier Syst, 2005; 22(3): 215– 94.
7. Beg S, Swain S, Rahman M, Hasnain MS, Imam SS. Application of design of experiments (DoE) in pharmaceutical product and process optimization. In: Pharmaceutical Quality by Design. United States: Academic Press, 2019; 43–64.